retatrutide 2025 trial results Timeline: Week-by-Week (48 Weeks) Lilly orforglipron oral GLP-1 phase

Tirzepatide is the better-evidenced molecule for perimenopausal women, with about 23% body weight loss versus 3% on placebo in a SURMOUNT-1 post-hoc analysis

In 2025 and 2026 the two programs moved in opposite directions

The difference lies in manufacturing, regulatory oversight, and formulation

And surprisingly, a new analyst report from Morgan Stanley $MS published this month suggests these gyms are making the right move

What surprised me even more is that Nano Microneedle Patch is different from other fast weight-loss products

Skincare Is Responding to the Side Effects Lip products, skincare, hair styling, and fragrances were four of the top 14 categories producing the highest sales gains in the first half of 2025